Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Abzena PLC sees momentum as acquisitions bed down

The drug developer and pharma services group acquired PacificGMP, a contract manufacturing business, in September and contract chemist TCRS in December.
Abzena PLC sees momentum as acquisitions bed down
Abzena has interests in eleven drugs currently under development, two of which are in phase II trials.

Abzena (LON:ABZA) says both its recent US acquisitions have bedded down well.

The group acquired PacificGMP, a contract manufacturing business, in September and contract chemist TCRS in December.

Bookings through both have been strong and have benefited from access to Abzena's immunogenicity assessment, antibody engineering and manufacturing technologies.

In January, Abzena's ThioBridge arm, a specialist in linking antibodies to other drugs, signed a licence agreement that could see it earn up to US$150mln in fees, royalties and milestone payments from an unnamed partner.

It has also just teed up a marketing alliance with antibody discovery services company, FairJourney Biologics (Portugal) to offer antibody discovery services  and with FairJourney Biologics to offer immunogenicity assessment and analytics. 

Abzena also has interests in eleven drugs currently under development, two of which are in phase II trials.

John Burt, chief executive, said:  "Progress has been strong during the period.

“The agreement for ThioBridge with a large US biotech company demonstrates the value of our proprietary technology in creating novel ADCs. We continue to find new ways of expanding our range of offerings, by working with specialists such as FairJourney Biologics.   

“We expect to maintain this level of momentum for the foreseeable future,” he added.

PhilW.jpg
Why Invest In Abzena plc? Read More Here

Register here to be notified of future ABZA Company articles
View full ABZA profile

Abzena plc Timeline

Related Articles

brokerreport.jpg
January 25 2017
Analyst Vadim Alexandre, of the company’s broker Northland Capital, said Wednesday’s update provided “better visibility” on the trial timetable.
biotech_517925923_58abefa9e91cc.jpg
February 21 2017
“Our strategy of investing in future capacity will ensure our ability to provide quality service for this high level of customer need as our partners’ programmes progress,” said chief executive John Burt.
dimerix-CEO-Kathy-Harrisson-757.png
Thu
Dimerix Limited has recently received an R&D tax refund.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use